Acute ischemic stroke (AIS), commonly known as a blockage or clot stroke, occurs when blood flow to an area of the brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients. AIS accounts for around 85% of the total strokes caused majorly due to atherosclerosis or blood vessel weakness. Clot dissolving drugs known as thrombolytics and endovascular thrombectomy are the most common treatment options available for AIS patients. Thrombolysis helps dissolve blood clots by using medications whereas thrombectomy removes clots through minimally invasive surgery.
The global AIS market is estimated to be valued at US$ 15 Billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Increased adoption of technologically advanced therapies is expected to be flourished by the AIS market over the forecast period. Interventional therapies like thrombectomy have significantly improved the clinical outcomes of AIS patients and gained widespread adoption globally. The latest generation mechanical thrombectomy devices have further simplified the procedures while achieving higher recanalization rates. Recent clinical trials such as DAWN, DEFUSE 3, and REVASCAT demonstrated better efficacy and safety of the extended window thrombectomy up to 24 hours after the stroke onset. This has expanded the eligible patient population and enabled more patients to receive timely treatment. Technological advancements are therefore enabling more effective management of AIS, thereby driving the market growth.
The acute ischemic stroke (AIS) market is segmented into devices and drugs. The devices segment currently dominates the market and accounts for the largest market share owing to the rising adoption of stent retrievers and aspiration devices for faster revascularization. These devices are widely being used for minimally invasive endovascular thrombectomy procedures.
Political: Governments across countries are focused on reducing the burden of stroke through public healthcare initiatives and awareness programs. Favorable reimbursement policies are boosting the adoption of high-cost endovascular devices.
Economic: Rising healthcare expenditures, growing per capita incomes, and increasing demand for advanced treatment options are fueling the market growth. However, high costs of endovascular devices can restrain the market to some extent.
Social: Growing geriatric population prone to chronic diseases and changing lifestyle leading to hypertension and diabetes are increasing the risk of AIS.Advancing healthcare infrastructure and awareness are encouraging people to seek proper treatment.
Technological: Rapid advances in devices such as stent retrievers and aspiration catheters enable quick recanalization of blocked blood vessels. Innovations are helping expand the therapeutic window for revascularization.
The Global Acute Ischemic Stroke (AIS) Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global AIS market is estimated to be valued at US$ 15 Billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
North America currently dominates the market owing to advanced healthcare infrastructure, favorable reimbursement policies, and rising government support for R&D activities.The Asia Pacific region is projected to grow at the fastest pace during the forecast period driven by improving access to healthcare facilities amid rising medical tourism, increasing healthcare expenditures, and growing focus of key players.
Key players operating in the acute ischemic stroke (AIS) market are Stryker Corporation, Medtronic Plc, Johnson & Johnson, Terumo Corporation, Penumbra Inc., Abbott Laboratories, Merit Medical Systems Inc. Rapid advances in devices such as stent retrievers and aspiration catheters enable quick recanalization of blocked blood vessels. Innovations are helping expand the therapeutic window for revascularization.